Trimazosin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Trimazosin
Accession Number
DB09206
Type
Small Molecule
Groups
Experimental
Description

Trimazosin is a sympatholytic alpha blocker.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Trimazosin hydrochloride827T79ILE753746-46-6WXMXALSEIGHTOR-UHFFFAOYSA-N
Categories
UNII
31L760807H
CAS number
35795-16-5
Weight
Average: 435.481
Monoisotopic: 435.211783674
Chemical Formula
C20H29N5O6
InChI Key
YNZXWQJZEDLQEG-UHFFFAOYSA-N
InChI
InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)
IUPAC Name
2-hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
SMILES
COC1=CC2=C(N=C(N=C2N)N2CCN(CC2)C(=O)OCC(C)(C)O)C(OC)=C1OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Trimazosin.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Investigational
AcemetacinThe therapeutic efficacy of Trimazosin can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AdrafinilTrimazosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe risk or severity of hypotension can be increased when Trimazosin is combined with Agmatine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Trimazosin.Approved, Investigational
AliskirenTrimazosin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Withdrawn
AmbrisentanTrimazosin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronTrimazosin may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineTrimazosin may increase the hypotensive activities of Amifostine.Approved, Investigational
AmiodaroneThe risk or severity of hypotension can be increased when Trimazosin is combined with Amiodarone.Approved, Investigational
AmitrazTrimazosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineTrimazosin may increase the hypotensive activities of Amlodipine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Trimazosin.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Trimazosin is combined with Amrinone.Approved
AnisodamineTrimazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApraclonidineTrimazosin may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Trimazosin is combined with Aranidipine.Approved, Investigational
ArbutamineTrimazosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolTrimazosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Trimazosin.Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
AvanafilAvanafil may increase the hypotensive activities of Trimazosin.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Trimazosin is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Trimazosin is combined with Azimilide.Investigational
BarnidipineTrimazosin may increase the antihypertensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
BenazeprilTrimazosin may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Trimazosin is combined with Bencyclane.Experimental
BendroflumethiazideTrimazosin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe risk or severity of hypotension can be increased when Trimazosin is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Trimazosin.Withdrawn
BepridilTrimazosin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Trimazosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
BietaserpineTrimazosin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostTrimazosin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Trimazosin is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
BitolterolTrimazosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
BosentanBosentan may increase the hypotensive activities of Trimazosin.Approved, Investigational
BQ-123Trimazosin may increase the hypotensive activities of BQ-123.Investigational
BretyliumTrimazosin may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Trimazosin.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Trimazosin.Experimental
BucindololTrimazosin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Trimazosin.Experimental, Investigational
BunazosinTrimazosin may increase the antihypertensive activities of Bunazosin.Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
CadralazineTrimazosin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineTrimazosin may increase the hypotensive activities of Cafedrine.Investigational
CandesartanTrimazosin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilTrimazosin may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilTrimazosin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilTrimazosin may increase the hypotensive activities of Captopril.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Trimazosin is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Trimazosin is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Trimazosin.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Trimazosin.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Investigational
ChlorothiazideTrimazosin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneTrimazosin may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineTrimazosin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilTrimazosin may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Trimazosin is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Trimazosin is combined with Cinnarizine.Approved, Investigational
CirazolineTrimazosin may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolTrimazosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Trimazosin is combined with Clevidipine.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Trimazosin.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
CryptenamineTrimazosin may increase the hypotensive activities of Cryptenamine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Trimazosin is combined with Cyclandelate.Approved
CyclopenthiazideTrimazosin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideTrimazosin may increase the hypotensive activities of Cyclothiazide.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Trimazosin.Investigational
DarodipineThe risk or severity of hypotension can be increased when Trimazosin is combined with Darodipine.Experimental
DebrisoquinDebrisoquin may increase the hypotensive activities of Trimazosin.Approved, Investigational
DelaprilTrimazosin may increase the hypotensive activities of Delapril.Experimental
DeserpidineTrimazosin may increase the hypotensive activities of Deserpidine.Approved
DetomidineTrimazosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineTrimazosin may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Trimazosin.Approved
DiethylnorspermineTrimazosin may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineTrimazosin may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DiltiazemTrimazosin may increase the hypotensive activities of Diltiazem.Approved, Investigational
DipivefrinTrimazosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DobutamineTrimazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineTrimazosin may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DorzolamideTrimazosin may increase the hypotensive activities of Dorzolamide.Approved
DotarizineThe risk or severity of hypotension can be increased when Trimazosin is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Trimazosin.Approved
DroxidopaTrimazosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EfonidipineTrimazosin may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilTrimazosin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTrimazosin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineTrimazosin may increase the hypotensive activities of Endralazine.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
EperisoneThe risk or severity of hypotension can be increased when Trimazosin is combined with Eperisone.Approved, Investigational
EphedrineTrimazosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineTrimazosin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineTrimazosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EpoprostenolTrimazosin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTrimazosin may increase the hypotensive activities of Eprosartan.Approved
ErgotamineTrimazosin may decrease the vasoconstricting activities of Ergotamine.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
EthosuximideThe risk or severity of hypotension can be increased when Trimazosin is combined with Ethosuximide.Approved
EtilefrineTrimazosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
FelodipineTrimazosin may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Trimazosin is combined with Fendiline.Withdrawn
FenoldopamTrimazosin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolTrimazosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Ferulic acidTrimazosin may increase the hypotensive activities of Ferulic acid.Experimental
Fish oilThe risk or severity of hypotension can be increased when Trimazosin is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Trimazosin is combined with Flunarizine.Approved
FluspirileneThe risk or severity of hypotension can be increased when Trimazosin is combined with Fluspirilene.Approved, Investigational
FormoterolTrimazosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilTrimazosin may increase the hypotensive activities of Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Trimazosin.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Trimazosin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Trimazosin is combined with Gallopamil.Investigational
GuanabenzTrimazosin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelTrimazosin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineTrimazosin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTrimazosin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Trimazosin.Approved, Investigational
GuanoclorTrimazosin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTrimazosin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTrimazosin may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Trimazosin.Experimental
HexamethoniumTrimazosin may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineTrimazosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineTrimazosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Trimazosin.Experimental
HydralazineHydralazine may increase the hypotensive activities of Trimazosin.Approved
HydrochlorothiazideTrimazosin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTrimazosin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Trimazosin.Approved, Investigational
ImidaprilTrimazosin may increase the hypotensive activities of Imidapril.Investigational
IndapamideTrimazosin may increase the hypotensive activities of Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Trimazosin.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Trimazosin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Trimazosin.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Trimazosin.Withdrawn
IrbesartanTrimazosin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Trimazosin.Approved
IsoetarineTrimazosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsoprenalineTrimazosin may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineTrimazosin may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineTrimazosin may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinTrimazosin may increase the hypotensive activities of Ketanserin.Investigational
LabetalolLabetalol may increase the antihypertensive activities of Trimazosin.Approved
LacidipineTrimazosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Trimazosin is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Trimazosin.Investigational
LatanoprostTrimazosin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineTrimazosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Trimazosin is combined with Levetiracetam.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Trimazosin is combined with Lidoflazine.Experimental
LinsidomineTrimazosin may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilTrimazosin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineTrimazosin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Trimazosin is combined with Loperamide.Approved
LosartanTrimazosin may increase the hypotensive activities of Losartan.Approved
MacitentanTrimazosin may increase the hypotensive activities of Macitentan.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Trimazosin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineTrimazosin may increase the hypotensive activities of Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Trimazosin.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Trimazosin.Approved, Investigational
MedetomidineTrimazosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MentholThe risk or severity of hypotension can be increased when Trimazosin is combined with Menthol.Approved
MephentermineTrimazosin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
MetaraminolTrimazosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethoserpidineTrimazosin may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineTrimazosin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineTrimazosin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Trimazosin is combined with Methsuximide.Approved
MethyldopaTrimazosin may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Trimazosin.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Trimazosin.Approved, Investigational
MetipranololTrimazosin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneTrimazosin may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Investigational
MetyrosineTrimazosin may increase the hypotensive activities of Metyrosine.Approved
MibefradilTrimazosin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineTrimazosin may decrease the vasoconstricting activities of Midodrine.Approved
MinaprineMinaprine may increase the hypotensive activities of Trimazosin.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Trimazosin.Approved, Investigational
MirabegronTrimazosin may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Trimazosin.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Trimazosin.Approved, Investigational
MoexiprilTrimazosin may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Trimazosin.Approved, Investigational
MoxonidineTrimazosin may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineTrimazosin may increase the hypotensive activities of Muzolimine.Experimental
NadololNadolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
NaftopidilTrimazosin may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineTrimazosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Trimazosin.Withdrawn
NicardipineTrimazosin may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilTrimazosin may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Trimazosin is combined with Nifedipine.Approved
NiguldipineTrimazosin may increase the hypotensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Trimazosin is combined with Niludipine.Experimental
NilvadipineTrimazosin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Trimazosin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineTrimazosin may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineTrimazosin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineTrimazosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Trimazosin.Approved, Investigational
NorepinephrineTrimazosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineTrimazosin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinTrimazosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabTrimazosin may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Trimazosin.Withdrawn
OctopamineTrimazosin may decrease the vasoconstricting activities of Octopamine.Experimental
OlmesartanTrimazosin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolTrimazosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatTrimazosin may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineTrimazosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Trimazosin is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
OxyfedrineTrimazosin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineTrimazosin may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Trimazosin.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Investigational
PentoliniumTrimazosin may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trimazosin.Approved, Investigational
PerindoprilTrimazosin may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Trimazosin.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Trimazosin.Withdrawn
PhenoxybenzamineTrimazosin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Trimazosin.Withdrawn
PhentolamineTrimazosin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineTrimazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineTrimazosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilPinacidil may increase the hypotensive activities of Trimazosin.Approved
PinaveriumThe risk or severity of hypotension can be increased when Trimazosin is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Investigational
PirbuterolTrimazosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Trimazosin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Trimazosin.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Trimazosin.Experimental
PolythiazideTrimazosin may increase the hypotensive activities of Polythiazide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
PrazosinPrazosin may increase the antihypertensive activities of Trimazosin.Approved
PrenalterolTrimazosin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Trimazosin is combined with Prenylamine.Withdrawn
ProcarbazineProcarbazine may increase the hypotensive activities of Trimazosin.Approved, Investigational
ProcaterolTrimazosin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PropranololPropranolol may increase the orthostatic hypotensive activities of Trimazosin.Approved, Investigational
PseudoephedrineTrimazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuinaprilTrimazosin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Trimazosin.Approved
RacepinephrineTrimazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineTrimazosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilTrimazosin may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Trimazosin.Approved
RemikirenTrimazosin may increase the hypotensive activities of Remikiren.Approved
ReproterolTrimazosin may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineTrimazosin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Trimazosin.Approved, Investigational
RilmenidineTrimazosin may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RimiterolTrimazosin may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatTrimazosin may increase the hypotensive activities of Riociguat.Approved
RitobegronTrimazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineTrimazosin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RituximabTrimazosin may increase the hypotensive activities of Rituximab.Approved
RomifidineTrimazosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
SafrazineSafrazine may increase the hypotensive activities of Trimazosin.Withdrawn
SalbutamolTrimazosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolTrimazosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanTrimazosin may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Trimazosin.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Trimazosin is combined with Seletracetam.Investigational
SelexipagTrimazosin may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the hypotensive activities of Trimazosin.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Trimazosin.Approved
SitaxentanTrimazosin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolabegronTrimazosin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Trimazosin.Approved
SpiraprilTrimazosin may increase the hypotensive activities of Spirapril.Approved
SynephrineTrimazosin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Trimazosin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Trimazosin.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Trimazosin.Approved, Investigational
TelmisartanTrimazosin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilTrimazosin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Trimazosin.Approved
TerbutalineTrimazosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerlipressinTrimazosin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineThe risk or severity of hypotension can be increased when Trimazosin is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TetrahydropalmatineTrimazosin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineTrimazosin may increase the hypotensive activities of Theodrenaline.Investigational
TiboloneTrimazosin may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTrimazosin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Trimazosin.Approved
TizanidineTrimazosin may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineTrimazosin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Trimazosin is combined with Tolfenamic Acid.Approved, Investigational
TolonidineTrimazosin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Trimazosin.Approved
TorasemideTrimazosin may increase the hypotensive activities of Torasemide.Approved
TrandolaprilTrimazosin may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Trimazosin is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Trimazosin.Approved, Investigational
TravoprostTrimazosin may increase the hypotensive activities of Travoprost.Approved
TreprostinilTrimazosin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretoquinolTrimazosin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrichlormethiazideTrimazosin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimebutineThe risk or severity of hypotension can be increased when Trimazosin is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Trimazosin is combined with Trimethadione.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Trimazosin.Approved, Investigational
TulobuterolTrimazosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Trimazosin.Approved, Investigational
UnoprostoneTrimazosin may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilTrimazosin may increase the antihypertensive activities of Urapidil.Investigational
ValsartanTrimazosin may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Trimazosin.Approved
VerapamilThe risk or severity of hypotension can be increased when Trimazosin is combined with Verapamil.Approved
VincamineTrimazosin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTrimazosin may increase the hypotensive activities of Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Trimazosin is combined with WIN 55212-2.Experimental
XamoterolTrimazosin may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideTrimazosin may increase the hypotensive activities of Xipamide.Experimental
XylazineTrimazosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineTrimazosin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Trimazosin.Approved, Investigational, Vet Approved
ZiconotideThe risk or severity of hypotension can be increased when Trimazosin is combined with Ziconotide.Approved
ZofenoprilTrimazosin may increase the hypotensive activities of Zofenopril.Experimental
ZonisamideThe risk or severity of hypotension can be increased when Trimazosin is combined with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. van Kalken CK, van der Meulen J, Oe PL, Vriesendorp R, Donker AJ: Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension. Eur J Clin Pharmacol. 1986;31(1):63-8. [PubMed:3780829]
External Links
PubChem Compound
37264
PubChem Substance
310265114
ChemSpider
34203
ChEBI
135710
ChEMBL
CHEMBL513301
Wikipedia
Trimazosin
ATC Codes
C02CA03 — Trimazosin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3669968No1972-06-131992-06-13Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.56 mg/mLALOGPS
logP1.35ALOGPS
logP1.2ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.59ChemAxon
pKa (Strongest Basic)5.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area132.5 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity114.87 m3·mol-1ChemAxon
Polarizability46.3 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Quinazolinamines / Piperazine carboxylic acids / Anisoles / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Imidolactams / Tertiary alcohols / Heteroaromatic compounds / Carbamate esters
show 7 more
Substituents
N-arylpiperazine / Quinazolinamine / Diazanaphthalene / Quinazoline / Piperazine-1-carboxylic acid / Anisole / Dialkylarylamine / Alkyl aryl ether / Aminopyrimidine / Pyrimidine
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 19, 2015 14:32 / Updated on May 02, 2018 01:33